Stock Track | Roivant Sciences Soars 5.13% on Better-Than-Expected Earnings and Clinical Trial Progress

Stock Track

May 29

Roivant Sciences Ltd. (ROIV) stock is soaring 5.13% in intraday trading, outperforming the broader market's positive trend. The biotechnology company's shares are gaining momentum following the release of its fourth-quarter financial results and updates on its clinical trials.

Roivant reported a narrower-than-expected loss for the quarter ended March 31, 2025. The company posted a net loss of $0.29 per share, beating analysts' expectations of a $0.31 loss. However, revenue fell short of estimates, coming in at $7.57 million compared to the expected $54.07 million. Despite the revenue miss, investors seem to be focusing on the company's ability to control costs and narrow its losses.

Adding to the positive sentiment, Roivant announced that its Valor Phase 3 study evaluating brepocitinib in patients with dermatomyositis is now fully enrolled. This milestone in the clinical development of brepocitinib, a potential treatment for autoimmune diseases, signals progress in the company's pipeline. The broader market optimism, with the NASDAQ Composite Index and Dow Jones Industrial Average both rising, may also be contributing to Roivant's stock performance today.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1157013785"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157013785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157013785?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157013785","market":"hk","top_or_hot":-1,"title":"Stock Track | Roivant Sciences Soars 5.13% on Better-Than-Expected Earnings and Clinical Trial Progress","media":"Stock Track","content":"<p>Roivant Sciences Ltd. (ROIV) stock is soaring 5.13% in intraday trading, outperforming the broader market's positive trend. The biotechnology company's shares are gaining momentum following the release of its fourth-quarter financial results and updates on its clinical trials.</p>\n\n<p>Roivant reported a narrower-than-expected loss for the quarter ended March 31, 2025. The company posted a net loss of $0.29 per share, beating analysts' expectations of a $0.31 loss. However, revenue fell short of estimates, coming in at $7.57 million compared to the expected $54.07 million. Despite the revenue miss, investors seem to be focusing on the company's ability to control costs and narrow its losses.</p>\n\n<p>Adding to the positive sentiment, Roivant announced that its Valor Phase 3 study evaluating brepocitinib in patients with dermatomyositis is now fully enrolled. This milestone in the clinical development of brepocitinib, a potential treatment for autoimmune diseases, signals progress in the company's pipeline. The broader market optimism, with the NASDAQ Composite Index and Dow Jones Industrial Average both rising, may also be contributing to Roivant's stock performance today.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Roivant Sciences Soars 5.13% on Better-Than-Expected Earnings and Clinical Trial Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Roivant Sciences Soars 5.13% on Better-Than-Expected Earnings and Clinical Trial Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-29 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Roivant Sciences Ltd. (ROIV) stock is soaring 5.13% in intraday trading, outperforming the broader market's positive trend. The biotechnology company's shares are gaining momentum following the release of its fourth-quarter financial results and updates on its clinical trials.</p>\n\n<p>Roivant reported a narrower-than-expected loss for the quarter ended March 31, 2025. The company posted a net loss of $0.29 per share, beating analysts' expectations of a $0.31 loss. However, revenue fell short of estimates, coming in at $7.57 million compared to the expected $54.07 million. Despite the revenue miss, investors seem to be focusing on the company's ability to control costs and narrow its losses.</p>\n\n<p>Adding to the positive sentiment, Roivant announced that its Valor Phase 3 study evaluating brepocitinib in patients with dermatomyositis is now fully enrolled. This milestone in the clinical development of brepocitinib, a potential treatment for autoimmune diseases, signals progress in the company's pipeline. The broader market optimism, with the NASDAQ Composite Index and Dow Jones Industrial Average both rising, may also be contributing to Roivant's stock performance today.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ROIV","symbol_name":"Roivant Sciences Ltd.","start_time":0,"source_url":"","article_id":"1157013785","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157013785","pubTimestamp":1748531425,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Roivant Sciences Ltd.  stock is soaring 5.13% in intraday trading, outperforming the broader market's positive trend. The biotechnology company's shares are gaining momentum following the release of its fourth-quarter financial results and updates on its clinical trials.Roivant reported a narrower-than-expected loss for the quarter ended March 31, 2025. The company posted a net loss of $0.29 per share, beating analysts' expectations of a $0.31 loss. However, revenue fell short of estimates, comi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ROIV":"Roivant Sciences Ltd."},"translate_title":"股票赛道Roivant Sciences因好于预期的盈利和临床试验进展而飙升5.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1},"content_text":"Roivant Sciences Ltd. (ROIV) stock is soaring 5.13% in intraday trading, outperforming the broader market's positive trend. The biotechnology company's shares are gaining momentum following the release of its fourth-quarter financial results and updates on its clinical trials.\nRoivant reported a narrower-than-expected loss for the quarter ended March 31, 2025. The company posted a net loss of $0.29 per share, beating analysts' expectations of a $0.31 loss. However, revenue fell short of estimates, coming in at $7.57 million compared to the expected $54.07 million. Despite the revenue miss, investors seem to be focusing on the company's ability to control costs and narrow its losses.\nAdding to the positive sentiment, Roivant announced that its Valor Phase 3 study evaluating brepocitinib in patients with dermatomyositis is now fully enrolled. This milestone in the clinical development of brepocitinib, a potential treatment for autoimmune diseases, signals progress in the company's pipeline. The broader market optimism, with the NASDAQ Composite Index and Dow Jones Industrial Average both rising, may also be contributing to Roivant's stock performance today.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}